These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Ioset JR; Chang S Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842 [TBL] [Abstract][Full Text] [Related]
4. The Future of Drug Development for Neglected Tropical Diseases: How the European Commission Can Continue to Make a Difference. Pierce RJ; MacDougall J; Leurs R; Costi MP Trends Parasitol; 2017 Aug; 33(8):581-583. PubMed ID: 28529130 [TBL] [Abstract][Full Text] [Related]
5. Toxins and drug discovery. Harvey AL Toxicon; 2014 Dec; 92():193-200. PubMed ID: 25448391 [TBL] [Abstract][Full Text] [Related]
6. Drug discovery and development for neglected diseases: the DNDi model. Chatelain E; Ioset JR Drug Des Devel Ther; 2011 Mar; 5():175-81. PubMed ID: 21552487 [TBL] [Abstract][Full Text] [Related]
7. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Katsuno K; Burrows JN; Duncan K; Hooft van Huijsduijnen R; Kaneko T; Kita K; Mowbray CE; Schmatz D; Warner P; Slingsby BT Nat Rev Drug Discov; 2015 Nov; 14(11):751-8. PubMed ID: 26435527 [TBL] [Abstract][Full Text] [Related]
8. Drugs for neglected diseases: part II. Kaneko T Future Med Chem; 2011 Sep; 3(11):1329-30. PubMed ID: 21879837 [No Abstract] [Full Text] [Related]
9. In silico repositioning of approved drugs for rare and neglected diseases. Ekins S; Williams AJ; Krasowski MD; Freundlich JS Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136 [TBL] [Abstract][Full Text] [Related]
10. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
11. Progress in neglected disease drug discovery. Hopkins AL; Wyatt PG Curr Top Med Chem; 2011; 11(10):1215. PubMed ID: 21401510 [No Abstract] [Full Text] [Related]
14. Yeast as a potential vehicle for neglected tropical disease drug discovery. Denny PW; Steel PG J Biomol Screen; 2015 Jan; 20(1):56-63. PubMed ID: 25121554 [TBL] [Abstract][Full Text] [Related]
15. Repurposing strategies for tropical disease drug discovery. Klug DM; Gelb MH; Pollastri MP Bioorg Med Chem Lett; 2016 Jun; 26(11):2569-76. PubMed ID: 27080183 [TBL] [Abstract][Full Text] [Related]
16. Finding new hits in neglected disease projects: target or phenotypic based screening? Gilbert IH; Leroy D; Frearson JA Curr Top Med Chem; 2011; 11(10):1284-91. PubMed ID: 21401505 [TBL] [Abstract][Full Text] [Related]
18. Whole organism based techniques and approaches in early stage oncology drug discovery-patents and trends. Hampson RJ; Wyatt MD Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):183-91. PubMed ID: 21913888 [TBL] [Abstract][Full Text] [Related]
19. Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected Diseases. Bellera CL; Sbaraglini ML; Talevi A Curr Top Med Chem; 2018; 18(5):369-381. PubMed ID: 29741140 [TBL] [Abstract][Full Text] [Related]
20. Future treatment options for human African trypanosomiasis. Jones AJ; Avery VM Expert Rev Anti Infect Ther; 2015; 13(12):1429-32. PubMed ID: 26414688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]